DyNAbind
DyNAbind is a Dresden-based biotech company that develops proprietary DNA-Encoded Library technology for drug discovery, offering custom DEL screening campaigns and research-use kits to pharmaceutical, biotech, and academic customers seeking small molecule binders against challenging targets.
- Company typePrivate
- Founded2017
- HeadquartersDresden, Germany
- Headcount1–10
- GTM typeB2B
- OfferingServices
What DyNAbind does
DyNAbind GmbH is a privately held biotechnology company founded in 2017 and headquartered in Dresden, Germany. The company develops next-generation DNA-Encoded Library (DEL) technology for early-stage drug discovery, serving pharmaceutical companies, biotech firms, and academic research groups seeking small molecule binders against challenging targets including membrane proteins, protein-protein interactions, and 14-3-3 protein complexes. DyNAbind employs between 1 and 10 people and operates from a ~160 m2 laboratory and office facility in the BioInnovation Centre.
The company's core technology is built on three patented innovations: (i) Dynamic Libraries, a dual-DNA presentation architecture that continuously generates new structures during screening and delivers over 30-fold improved signal-to-noise ratios; (ii) the Path-Coding Algorithm, an informatic pipeline with built-in error proofing that reduces false positives and false negatives and increases usable sequences by over 37%; and (iii) the Binding Profiler system, an on-DNA biosensor technology that validates hits without resynthesis by returning kinetic data (on-rates, off-rates, dissociation constants). Together these components support a library collection exceeding 125 million fragment and small molecule structures and underwrite the company's positioning around hitting traditionally undruggable targets.
DyNAbind generates revenue through two streams: customized DEL screening campaigns sold directly to enterprise partners (fees project-based and not publicly disclosed) and DEL research-use kits containing over 370,000 fragment pairs distributed exclusively through MilliporeSigma. Go-to-market relies on industry conference participation (BioEurope, Swiss Biotech Day, BioJapan, EFMC ISMC, BioVaria), joint webinars with technology partners, and direct partnering outreach. Notable collaborations include AstraZeneca, Galapagos NV, Almirall, Heptares Therapeutics, OMass Therapeutics, Confo Therapeutics, Salipro Biotech, CEITEC, Northwestern University, University of Edinburgh, and Columbia University. The company received an EXIST Forschungstransfer grant from the German federal government in 2015 and closed a venture funding round in 2019 with European investors including HTGF, TGFS, and TUDAG.
DyNAbind firmographics
Firmographics- Name
- DyNAbind
- Legal name
- DyNAbind GmbH
- Website
- https://dynabind.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- DyNAbind is a Dresden-based biotech company that develops proprietary DNA-Encoded Library technology for drug discovery, offering custom DEL screening campaigns and research-use kits to pharmaceutical, biotech, and academic customers seeking small molecule binders against challenging targets.
- Ownership category
- akta.pro rank
DyNAbind industry classification
Industry- Product category
- Drug Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)
- akta.pro secondary industries
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where DyNAbind is headquartered
LocationHeadquarters
- HQ city
- Dresden
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
DyNAbind business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- DEL Screening Services: Customized DNA-Encoded Library screening campaigns tailored to partner drug discovery projects, including campaign design, deep analysis, and hit validation services.
- DEL Research Kits: Research-use DEL kits sold through distributor MilliporeSigma, containing custom-built libraries with over 370,000 fragment pairs plus access to online data analysis portal.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
DyNAbind product offering
Product offeringCore offering
DyNAbind develops and commercializes next-generation DNA-Encoded Library (DEL) technologies for drug discovery. Its core offerings include the Dynamic Library Platform with a patented dual-DNA presentation architecture, the Path-Coding Algorithm for error-proofed sequencing analysis, and the Binding Profiler on-DNA biosensor for kinetic hit validation. The company sells research-use DEL kits and performs customized DEL screening campaigns for pharmaceutical and academic partners.
Product overview
DyNAbind offers a next-generation platform of DNA-Encoded Library (DEL) technologies for drug discovery. The core offerings consist of the Dynamic Library Platform with dual-DNA presentation architecture, the Path-Coding Algorithm for data analysis, and the Binding Profiler Validation system. These are complemented by DEL research kits distributed through MilliporeSigma and full-service DNA-Encoded Library screening campaigns. The platform combines fragment-based drug discovery principles with DEL technology to deliver higher quality, more relevant medicinal chemistry starting points.
Differentiator
Problem solved
Functional benefit
Products and services
- DNA-Encoded Library Screening Campaigns Customized drug discovery campaigns for pharmaceutical companies, biotech firms, and academic institutions, including campaign design, deep sequencing analysis, and kinetic hit validation services tailored to partner-specific targets.
- DEL Research Kits Research-use DNA-encoded library kits containing multiple aliquots of a custom-built library with over 370,000 fragment pairs plus access to an online data analysis portal, sold exclusively through MilliporeSigma for DIY researchers and academic groups.
Quantifiable outcome
- Over 30-fold improved signal-to-noise ratios
- +2 more outcomes
Companies that use DyNAbind
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles3 records
DyNAbind technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
DyNAbind partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and supporting.
- Salipro Biotech ABcoreCollaboration combining Salipro's proprietary platform technology for membrane proteins with DyNAbind's Dynamic Library DEL technology to enable screening on difficult membrane protein targets like GPCRs, SLC transporters, and Ion Channels. Successfully identified small molecule binders confirmed via surface plasmon resonance.
- AstraZenecacoreCollaborative research partner in Nature Scientific Reports publication on DEL screening for membrane proteins. Partnered with Salipro Biotech, DyNAbind, and University of Copenhagen using Pannexin 1 channel as model system.
- PharmacelerasupportingJoint scientific collaboration combining DyNAbind's DEL screening with Pharmacelera's AI and 3D molecular descriptors for improved data post-processing and hit identification from DEL data.
- Galapagos NVcoreLong-term framework collaboration agreement for compound screening using DEL technologies for various indications including inflammation and fibrosis. Part of Galapagos' portfolio of clinical-stage first-in-class medicines.
- AlmirallcoreCollaboration for compound screening using DyNAbind's proprietary DEL technology to discover novel drug candidates for treating dermatological inflammation conditions.
- University of EdinburghsupportingCollaboration with Centres for Cardiovascular Science and Inflammation Research to discover novel fragment- and small molecule-based drug candidates for treatment of cystic fibrosis.
- Northwestern UniversitysupportingCollaboration with Professor Peter Penzes and Center for Autism and Neurodevelopment to discover novel drug candidates for neurodegenerative diseases.
- Heptares TherapeuticscoreCollaboration to find new drug candidates for GPCR targets. Combines DyNAbind's DEL technology with Heptares' membrane protein expertise to tackle historically difficult-to-drug membrane-bound proteins.
- CEITECsupportingStrategic alliance for discovery and development of drug candidates targeting human 14-3-3 protein complexes for cancer and neurodegenerative diseases based on research from Dr. Jozef Hritz's labs.
- MilliporeSigmacoreExclusive distributor for DyNAbind's research-use DEL kits containing over 370,000 fragment pairs plus online data analysis portal access. Makes DEL technology accessible to DIY researchers and academic groups.
- Confo TherapeuticssupportingDrug discovery collaboration combining DyNAbind's DEL technologies with Confo Therapeutics' capabilities.
- Columbia UniversitysupportingDrug discovery collaboration with Columbia University researchers.
- OMass TherapeuticssupportingCollaboration agreement for drug discovery utilizing DyNAbind's DEL platform.
Scale indicators4 records
Recent moves7 records
Expansion highlights6 records
DyNAbind competitors and assessment
Company assessmentDirect peers
- X-Chem Pharmaceuticals: X-Chem is one of the largest independent DNA-Encoded Library platforms offering custom DEL screening and a library of over 200 billion compounds. Directly comparable to DyNAbind as a fee-for-service DEL provider to pharma and biotech.
- HitGen: HitGen operates DEL screening services and a DEL-based drug discovery platform (DEL+DNA-tagged library of billions of compounds). Directly comparable as a DEL service and library provider competing for the same pharma screening contracts.
- Philochem: Philochem is a Switzerland-based DEL technology company offering DEL screening services and proprietary libraries. Directly comparable in size, geographic region (DACH + EU), and DEL service offering.
- Vipergen: Vipergen provides DEL-based screening services including on-DNA kinetic and binder-confirmation assays. Comparable to DyNAbind as a specialized DEL service provider targeting difficult drug targets.
- Edelris: Edelris is a French CRO specializing in DEL technology (KeymicalTM library) and fragment-based discovery. Closely comparable to DyNAbind as a European DEL service provider of similar scale.
Broad incumbents
- WuXi AppTec (DEL platform): WuXi AppTec offers DNA-Encoded Library screening among its broader CRO/preclinical services. A large incumbent competing on scale and pricing; comparable technology within a much broader service portfolio.
- Charles River Laboratories: Charles River provides drug discovery services including DEL-style screening through its early-discovery portfolio. Comparable as a CRO competitor that pharma may route screening budgets to.
- Nuevolution (Amgen): Originally an independent DEL platform (acquired by Amgen in 2015), Nuevolution's Chemetics platform exemplifies the in-house DEL path large pharma have chosen. Comparable as a DEL technology benchmark and competitive alternative if pharma insources.
Emerging players
- Pharmacelera: Pharmacelera provides AI/3D molecular descriptor tools for DEL and virtual screening data interpretation. Comparable to DyNAbind as a collaborator/adjacent player in the AI-enabled DEL data analysis stack.
- Salipro Biotech AB: Salipro develops a proprietary membrane-protein platform enabling DEL screening on GPCRs, ion channels, and SLC transporters. Comparable as a partner and adjacent technology enabling the same difficult-target workflows DyNAbind addresses.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
DyNAbind social profiles
Digital presenceDyNAbind financial estimates
Financial estimateRevenue estimate
Valuation estimate
DyNAbind leadership team
Management profileNumber of profiles
Profiles4 records
DyNAbind funding detail
Funding detailFunding overview
Funding rounds1 record
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DyNAbind M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DyNAbind
What does DyNAbind do?
DyNAbind develops and commercializes next-generation DNA-Encoded Library (DEL) technologies for drug discovery. Its core offerings include the Dynamic Library Platform with a patented dual-DNA presentation architecture, the Path-Coding Algorithm for error-proofed sequencing analysis, and the Binding Profiler on-DNA biosensor for kinetic hit validation. The company sells research-use DEL kits and performs customized DEL screening campaigns for pharmaceutical and academic partners.
Is DyNAbind a public or private company?
DyNAbind is a private company. It is classified as venture growth investor backed and is currently operating.
When was DyNAbind founded?
DyNAbind was founded in 2017. It employs 1 to 10 people.
Where is DyNAbind based?
DyNAbind is headquartered in Dresden, Germany, in the Europe region.
How does DyNAbind make money?
Two revenue lines are on record. DEL Screening Services are the primary driver. The others are DEL Research Kits.
Who are DyNAbind's main competitors?
Direct peers on record are X-Chem Pharmaceuticals, HitGen, Philochem, Vipergen and Edelris. Broad incumbents are WuXi AppTec (DEL platform), Charles River Laboratories and Nuevolution (Amgen). Emerging players are Pharmacelera and Salipro Biotech AB.
Does DyNAbind have an API?
No public API is recorded for DyNAbind.
What industry is DyNAbind in?
DyNAbind's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAL, Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries), with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.